If you’re a fan of Coopervision’s MyDay Multifocal—with its three distinct approaches for different levels of presbyopia—but wish you could have that in the company’s more affordably priced Clariti line of products, today’s your lucky day. The company just announced a new multifocal for its Clariti 1-day brand that offers more flexibility to better suit individual patient needs.

The three lens designs available in Clariti 1-day Multifocal 3 Add contact lenses.
The three lens designs available in Clariti 1-day Multifocal 3 Add contact lenses. Click image to enlarge.

Called “Clariti 1-day Multifocal 3 Add,” the lens’s hallmark feature is its three add power designs: low (+0.75D to +1.25D), medium (+1.50D to +1.75D) and high (+2.00D to +2.50) with a wider distance component in the low add lens, a sizable transition zone in the medium add and a spherical center-near correction in the high add lens. The company calls this its “binocular progressive system” and it will now be a feature of both the MyDay and Clariti lines.

Clariti 1-day Multifocal 3 Add will replace the existing Clariti 1-day Multifocal, which only offered two add power options, in the company’s product line. To ease the transition for practices, both lenses will remain in the company’s lineup for a period of time, a spokesperson says. Details around the phase-out of the original Clariti 1-day Multifocal will be shared with customers in the next few weeks.

The newer lens will also be offered in more sphere powers (-12.00D to +8.00D) than the older design, according to the company, and the lens edge profile has been upgraded from the original Clariti 1-day Multifocal for improved stability and ease of fit, a press release explains. This lens will also feature the company’s “WetLoc” approach to SiHy polymerization, resulting in absolute moisture retention of 98.8%, the company reports.

In CooperVision’s press release on the 3 Add lens, the company cites the results of a recent company-funded clinical study finding that 98% of patients were fit with their final prescription with just one or two attempts.

For more information, go to www.coopervision.com.